RedHill Biopharma (RDHL) Current Deferred Revenue (2018 - 2025)

RedHill Biopharma (RDHL) has 8 years of Current Deferred Revenue data on file, last reported at -$3.0 million in Q4 2025.

• On a quarterly basis, Current Deferred Revenue fell 118.45% year-over-year to -$3.0 million in Q4 2025; TTM through Dec 2025 was -$3.0 million, a 118.45% decrease from a year earlier, with the FY2025 full-year figure at $6.3 million, down 32.13% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at -$3.0 million, down from $10.5 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for RDHL reached as high as $41.8 million in Q3 2022 and fell as low as -$37.2 million in Q4 2023.
• Historically, Current Deferred Revenue has averaged $14.2 million across 5 years, with a median of $22.7 million in 2021.
• Across the five-year window, Current Deferred Revenue soared 6951.06% in 2021 and plunged 316.89% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $30.7 million in 2021, then plunged by 44.13% to $17.2 million in 2022, then plunged by 316.89% to -$37.2 million in 2023, then surged by 96.33% to -$1.4 million in 2024, then sank by 118.45% to -$3.0 million in 2025.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were -$3.0 million in Q4 2025, $10.5 million in Q2 2025, and -$1.4 million in Q4 2024.